Supplementary Figure S6 from Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy

Toshiaki Iwase; Evan N. Cohen; Hui Gao; Angela Alexander; Megumi Kai; Vivian Chiv; Xiaoping Wang; Savitri Krishnamurthy; Diane D. Liu; Yu Shen; Kumiko Kida; Alexandre Reuben; Rachel M. Layman; David L. Ramírez; Debasish Tripathy; Stacy L. Moulder; Clinton Yam; Vicente Valero; Bora Lim; James M. Reuben; Naoto T. Ueno

doi:10.1158/1078-0432.25956635

Abstract

Supplementary Figure 6. Progression-free survival and overall survival stratified by clonality in patients with PD-L1–negative tumors per IHC analysis (N = 32).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Iwase et al. (2024) studied this question.

synapsesocial.com/papers/68e66839b6db6435875f3dca https://doi.org/10.1158/1078-0432.25956635

View Full Paper

Ask AI

Bookmark

Share

Supplementary Figure S6 from Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy

Abstract

Discussion

Cite This Study

Supplementary Figure S6 from Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy

Abstract

Discussion

Cite This Study

Keep reading

More related papers

Keep reading

More related papers